In addition, a favorable prognostic effect of CD20+ TAB can be linked only to distinct histologic or molecular cancer subtypes, as shown for breast cancer (in ER−, basal, and HER2+, but not triple-negative subtypes53,54), ovarian cancer (in high-grade serous, but not other subtypes55) and mesothelioma (in the epithelioid, but not non-epithelioid subtype56). This evidence concerns the gene ERBB2 and ovarian carcinoma.